PRECLINICAL ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE DENINTUZUMAB MAFODOTIN (SGN-CD19A) AGAINST PEDIATRIC ALL XENOGRAFTS

BACKGROUND. Denintuzumab mafodotin (SGN-CD19A) is a CD19-targeting antibody-drug conjugate (ADC), comprising a monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin F (MMAF). Since denintuzumab mafodotin has previously shown activity against B-cell malignancies in early stage...

Full description

Saved in:
Bibliographic Details
Published in:Pediatr Blood Cancer
Main Authors: Jones, Luke, McCalmont, Hannah, Evans, Kathryn, Mayoh, Chelsea, Kurmasheva, Raushan T., Billups, Catherine A., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6588422/
https://ncbi.nlm.nih.gov/pubmed/31012549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27765
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items